Latest On Rubius Therapeutics, Inc (RUBY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-22 17:10 EST | News | Rubius Therapeutics adds 10% on plan for liquidation | N/A |  |
| 2022-11-02 22:34 EST | News | Rubius stock falls over 5% after hours on strategic review, more job cuts | N/A | |
| 2022-09-13 17:01 EST | News | Rubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforce | N/A | |
| 2022-08-10 05:06 EST | News | Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03 | N/A | |
| 2022-06-20 00:49 EST | News | Rubius: Poor Data, Punishing Environment, Beaten Stock | N/A | |
| 2022-05-12 04:13 EST | News | Rubius price target lowered at H.C. Wainwright on trial update for cellular therapy | N/A | |
| 2022-05-10 12:59 EST | News | Rubius Therapeutics GAAP EPS of -$0.58 beats by $0.01 | N/A | |
| 2022-04-26 02:06 EST | News | Rubius Therapeutics up 34% after insider buy | N/A | |
| 2022-04-12 01:29 EST | News | Rubius price targets slashed on underwhelming cancer data | N/A | |
| 2022-04-12 01:29 EST | News | Rubius Therapeutics tumbles 20% on lowered price target due to disappointing RTX-240 data | N/A | |
| 2022-04-08 20:19 EST | News | Rubius Therapeutics falls 45% after updated early-stage data on solid tumors candidate | N/A | |
| 2022-03-22 02:13 EST | News | Rubius Looks Attractive Before AACR Data Readout | N/A | |
| 2022-02-25 13:42 EST | News | Rubius Therapeutics GAAP EPS of -$0.61 misses by $0.02 | N/A | |
| 2022-02-11 08:33 EST | News | Rubius Therapeutics (RUBY) Investor Presentation IP - Slideshow | N/A | |
| 2022-01-13 20:24 EST | News | Rubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumors | N/A | |
| 2022-01-13 03:55 EST | News | Rubius Therapeutics (RUBY) presents at JP Morgan 40th Annual Virtual Healthcare Conference (Slideshow) | N/A | |
| 2021-12-16 13:02 EST | News | Rubius to report additional Phase 1 data for RTX-240 in solid tumors next quarter | N/A | |
| 2021-11-08 17:58 EST | News | Rubius Therapeutics EPS beats by $0.02 | N/A | |
| 2021-10-12 12:10 EST | News | Warning: RUBY is at high risk of performing badly | N/A | |
| 2021-08-09 14:04 EST | News | Rubius Therapeutics EPS misses by $0.06 | N/A | |
| 2021-07-30 00:46 EST | News | Rubius Therapeutics appoints new operations chief | N/A | |
| 2021-07-21 22:12 EST | News | Rubius Therapeutics doses first patient in RTX-240 cancer study | N/A | |
| 2021-07-21 21:59 EST | News | Our Read On Rubius Therapeutics | N/A | |
| 2021-04-09 09:51 EST | News | Rubius Therapeutics to present early-stage RTX-240 study results at AACR | N/A | |
| 2021-03-17 07:30 EST | News | Rubius Therapeutics falls on initial data for RTX-240 in solid tumors | N/A | |
| 2021-03-17 07:27 EST | News | Rubius shares soar 84% on solid tumor data, Wainwright PT increase | N/A | |
| 2021-03-17 07:27 EST | News | Rubius Therapeutics secures $150M capital raise | N/A | |
| 2021-03-17 07:24 EST | News | Rubius Therapeutics prices upsized $200M public offering | N/A | |
| 2021-03-16 21:55 EST | Analyst Rating | The Analyst Target Price has increased from $13.9 to $27.4. | Buy | |
| 2021-02-27 01:01 EST | News | Rubius Therapeutics (RUBY) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow | N/A | |
| 2021-02-25 14:34 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-25 14:34 EST | Analyst Rating | The Analyst Target Price has increased from $11.33 to $13.9. | Buy | |
| 2021-02-24 12:19 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-24 12:19 EST | Earnings Estimate | An EPS average of -$1.71 is estimated for the 2022 year. | Sell | |
| 2021-02-24 12:19 EST | Earnings Estimate | An EPS average of -$0.48 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-24 12:19 EST | Analyst Rating | The Analyst Target Price has decreased from $11.5 to $11.33. | Sell | |
| 2021-02-23 20:12 EST | News | Rubius Therapeutics drops 5% despite Q4 beat | N/A | |
| 2021-01-29 08:29 EST | Analyst Rating | The Analyst Target Price has increased from $10.29 to $11.5. | Neutral | |
| 2021-01-26 12:53 EST | News | Rubius: Watson, We Have No Data | N/A | |
| 2021-01-20 08:28 EST | Analyst Rating | The Analyst Target Price has increased from $9.57 to $10.29. | Buy | |
| 2021-01-15 00:40 EST | News | Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow | N/A | |
| 2021-01-12 08:28 EST | Analyst Rating | The Analyst Target Price has decreased from $10.67 to $9.57. | Neutral | |
| 2020-11-26 21:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 13:11 EST | Analyst Rating | The Analyst Target Price has increased from $9.57 to $10.67. | Buy | |
| 2020-11-12 05:09 EST | Analyst Rating | The Analyst Target Price has increased from $9.43 to $9.57. | Buy | |
| 2020-11-11 12:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 13:05 EST | Earnings Estimate | An EPS average of -$0.53 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-09 18:23 EST | News | Rubius Therapeutics EPS misses by $0.01 | N/A | |
| 2020-11-08 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:02 EST | Financials | Company financials have been released. | Neutral | |
About Rubius Therapeutics, Inc (RUBY):
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
General
- Name Rubius Therapeutics, Inc
- Symbol RUBY
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 204
- Fiscal Year EndDecember
- IPO Date2018-07-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.rubiustx.com
View More
Valuation
- Price/Book (Most Recent Quarter) 13.87
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.10
- Next Year EPS Estimate -$2.11
- Next Quarter EPS Estimate -$0.50
- Return on Assets -31%
- Return on Equity -81%
- Earnings Per Share -$1.70
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 1.97 billion
- EBITDA -130160000
- Analyst Target Price $27.4
- Book Value Per Share $1.75
View More
Share Statistics
- Shares Outstanding 81.18 million
- Shares Float 32.06 million
- % Held by Insiders 799%
- % Held by Institutions 94.8%
- Shares Short 7.5 million
- Shares Short Prior Month 7.41 million
- Short Ratio 7.92
- Short % of Float 28%
- Short % of Shares Outstanding 9%
View More
Technicals
- Beta 2.2
- 52 Week High $29.63
- 52 Week Low $3.83
- 50 Day Moving Average 13.94
- 200 Day Moving Average 8.21
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Rubius Therapeutics, Inc (RUBY) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Rubius Therapeutics, Inc (RUBY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-23 | $N/A | -$0.50 | -$0.53 | 4.94% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.51 | -$0.50 | -2.7% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.47 | -$0.50 | 6.47% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.60 | -$0.56 | -7.89% |
| 2019-12-31 | 2020-03-12 | $N/A | -$0.56 | -$0.64 | 12.57% |
| 2019-09-30 | 2019-11-14 | $N/A | -$0.59 | -$0.56 | -5.56% |
| 2019-06-30 | 2019-08-13 | $N/A | -$0.50 | -$0.48 | -3.28% |
| 2019-03-31 | 2019-05-15 | $N/A | -$0.42 | -$0.41 | -1.35% |
| 2018-12-31 | 2019-03-28 | $N/A | -$0.35 | -$0.42 | 16.51% |
| 2018-09-30 | 2018-11-13 | $N/A | -$0.42 | -$0.36 | -16.54% |
| 2018-06-30 | 2018-08-31 | $N/A | -$0.43 | -$0.30 | -41.68% |
Rubius Therapeutics, Inc (RUBY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 25.62 million | N/A | N/A | 36.19 million | 30.5 million |
| Income Before Tax | -40.54 million | N/A | N/A | -48.49 million | -44.47 million |
| Selling General Administrative | 14.1 million | N/A | N/A | 12.66 million | 14.93 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -38.83 million | N/A | N/A | -45.71 million | -45.43 million |
| Operating Income | -39.72 million | N/A | N/A | -48.85 million | -45.43 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | 297000 | N/A | N/A | 300000 | 956000 |
| Net Income From Continuing Operations | -40.54 million | N/A | N/A | -48.49 million | -44.47 million |
| Net Income Applicable to Common Shares | -40.54 million | -40.85 million | -37.85 million | N/A | -44.47 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | 92.15 million | 23.98 million | 6.77 million |
| Change to Liabilities | -989000 | 2.18 million | N/A | -4.22 million | 7.93 million |
| Total Cash Flow from Investing Activities | -26.13 million | -12.06 million | N/A | 10.7 million | -3.2 million |
| Net Borrowings | N/A | 25 million | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 486000 | 570000 | 350000 |
| Change to Operating Activities | 3.54 million | -3.09 million | N/A | 8.25 million | -227000 |
| Change in Cash | N/A | N/A | 52.62 million | -17.71 million | -31.6 million |
| Total Cash from Operating Activities | -28.53 million | -28.55 million | -40.02 million | -28.99 million | -28.75 million |
| Depreciation | N/A | N/A | 1.79 million | 701000 | 848000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 8.16 million | 8.44 million | N/A | 10.75 million | 9.72 million |
| Capital Expenditures | N/A | N/A | 2.85 million | 13.28 million | 9.97 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 136.23 million | N/A | 138.96 million | 113.17 million | 120.63 million |
| Total Stockholder Equity | 141.56 million | N/A | 205.47 million | 235.16 million | 274.21 million |
| Other Current Liabilities | 22.36 million | N/A | 286000 | 294000 | 322000 |
| Total Assets | 277.79 million | N/A | 344.43 million | 348.33 million | 394.84 million |
| Common Stock | 81000 | 81000 | 80000 | N/A | 80000 |
| Other Current Assets | 5.22 million | N/A | N/A | N/A | N/A |
| Retained Earnings | -480.47 million | -439.93 million | -399.08 million | -361.23 million | -312.74 million |
| Other Liabilities | N/A | 884000 | 630000 | N/A | 405000 |
| Other Assets | N/A | 1.88 million | 2.05 million | N/A | 2.09 million |
| Cash | 91.17 million | N/A | 129.16 million | 144.52 million | 91.9 million |
| Total Current Liabilities | 27.84 million | 30 million | 28.93 million | 27.35 million | 33.76 million |
| Other Stockholder Equity | 4000 | 32000 | 194000 | N/A | 75000 |
| Property, Plant & Equipment | 53.95 million | 96.12 million | 98.31 million | N/A | 103.48 million |
| Total Current Assets | 181.51 million | 214.36 million | 244.08 million | 245.88 million | 289.27 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 141.56 million | 173.12 million | 205.47 million | N/A | 274.21 million |
| Short Term Investments | 85.12 million | N/A | 107.37 million | 96.87 million | 191.39 million |
| Long Term Debt | 74.94 million | N/A | 74.74 million | 49.68 million | 49.6 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 5.48 million | 9.14 million | 9.83 million | 7.63 million | 7.18 million |
Rubius Therapeutics, Inc (RUBY) Chart:
Rubius Therapeutics, Inc (RUBY) News:
Below you will find a list of latest news for Rubius Therapeutics, Inc (RUBY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Rubius Therapeutics, Inc (RUBY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest RUBY Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 200 | $0.8926 |
| Jun 13, 2022 7:59 PM EST | 7 | $0.8926 |
| Jun 13, 2022 7:59 PM EST | 68 | $0.8926 |
| Jun 13, 2022 7:59 PM EST | 21 | $0.8926 |
| Jun 13, 2022 7:59 PM EST | 95 | $0.8926 |
Rubius Therapeutics, Inc (RUBY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920078435/0001104659-20-078435-index.htm |
| 2019-08-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1709401/000000000019012197/0000000000-19-012197-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000031506619001262/0000315066-19-001262-index.htm |
| 2019-11-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000031506619001755/0000315066-19-001755-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000031506620001145/0000315066-20-001145-index.htm |
| 2018-07-18 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1709401/000104746918005073/0001047469-18-005073-index.htm |
| 2019-04-12 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1709401/000104746919002211/0001047469-19-002211-index.htm |
| 2019-08-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1709401/000104746919004493/0001047469-19-004493-index.htm |
| 2020-04-09 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1709401/000104746920002200/0001047469-20-002200-index.htm |
| 2019-01-15 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000108887519000014/0001088875-19-000014-index.htm |
| 2020-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000108887520000018/0001088875-20-000018-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045597/0001104659-18-045597-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045598/0001104659-18-045598-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045599/0001104659-18-045599-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045600/0001104659-18-045600-index.htm |
| 2018-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045601/0001104659-18-045601-index.htm |
| 2018-07-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045764/0001104659-18-045764-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045771/0001104659-18-045771-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045772/0001104659-18-045772-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045773/0001104659-18-045773-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045774/0001104659-18-045774-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045775/0001104659-18-045775-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045776/0001104659-18-045776-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045777/0001104659-18-045777-index.htm |
| 2018-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918045778/0001104659-18-045778-index.htm |
| 2018-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046523/0001104659-18-046523-index.htm |
| 2018-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046526/0001104659-18-046526-index.htm |
| 2018-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046528/0001104659-18-046528-index.htm |
| 2018-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046530/0001104659-18-046530-index.htm |
| 2018-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046532/0001104659-18-046532-index.htm |
| 2018-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046534/0001104659-18-046534-index.htm |
| 2018-07-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046838/0001104659-18-046838-index.htm |
| 2018-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918048790/0001104659-18-048790-index.htm |
| 2018-08-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918054635/0001104659-18-054635-index.htm |
| 2018-08-31 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000110465918054637/0001104659-18-054637-index.htm |
| 2018-11-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465918065519/0001104659-18-065519-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918067460/0001104659-18-067460-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918067738/0001104659-18-067738-index.htm |
| 2018-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000110465918067739/0001104659-18-067739-index.htm |
| 2018-12-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465918074479/0001104659-18-074479-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm |
| 2019-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919002584/0001104659-19-002584-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919003193/0001104659-19-003193-index.htm |
| 2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919005603/0001104659-19-005603-index.htm |
| 2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919005604/0001104659-19-005604-index.htm |
| 2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919005605/0001104659-19-005605-index.htm |
| 2019-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919005606/0001104659-19-005606-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000110465919008821/0001104659-19-008821-index.htm |
| 2019-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919008822/0001104659-19-008822-index.htm |
| 2019-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919013736/0001104659-19-013736-index.htm |
| 2019-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm |
| 2019-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919017131/0001104659-19-017131-index.htm |
| 2019-03-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919017892/0001104659-19-017892-index.htm |
| 2019-03-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919018062/0001104659-19-018062-index.htm |
| 2019-04-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919019036/0001104659-19-019036-index.htm |
| 2019-04-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919020731/0001104659-19-020731-index.htm |
| 2019-04-12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1709401/000110465919021135/0001104659-19-021135-index.htm |
| 2019-04-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm |
| 2019-05-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919031516/0001104659-19-031516-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032118/0001104659-19-032118-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032119/0001104659-19-032119-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032120/0001104659-19-032120-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032121/0001104659-19-032121-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032122/0001104659-19-032122-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032123/0001104659-19-032123-index.htm |
| 2019-05-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919032124/0001104659-19-032124-index.htm |
| 2019-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-06-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm |
| 2019-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm |
| 2019-07-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm |
| 2019-08-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1709401/000110465919045115/0001104659-19-045115-index.htm |
| 2019-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919045429/0001104659-19-045429-index.htm |
| 2019-08-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1709401/000110465919046536/0001104659-19-046536-index.htm |
| 2019-09-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm |
| 2019-10-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919063717/0001104659-19-063717-index.htm |
| 2019-11-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919065987/0001104659-19-065987-index.htm |
| 2019-12-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919069692/0001104659-19-069692-index.htm |
| 2019-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919073590/0001104659-19-073590-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465919075314/0001104659-19-075314-index.htm |
| 2019-12-26 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465919076260/0001104659-19-076260-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920000769/0001104659-20-000769-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920003243/0001104659-20-003243-index.htm |
| 2020-01-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920003444/0001104659-20-003444-index.htm |
| 2020-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920007739/0001104659-20-007739-index.htm |
| 2020-01-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920009345/0001104659-20-009345-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920010062/0001104659-20-010062-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920010063/0001104659-20-010063-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920010064/0001104659-20-010064-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920010065/0001104659-20-010065-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920032144/0001104659-20-032144-index.htm |
| 2020-03-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920036113/0001104659-20-036113-index.htm |
| 2020-04-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1709401/000110465920044866/0001104659-20-044866-index.htm |
| 2020-04-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000110465920047001/0001104659-20-047001-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920059157/0001104659-20-059157-index.htm |
| 2020-05-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920065450/0001104659-20-065450-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920078435/0001104659-20-078435-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920092420/0001104659-20-092420-index.htm |
| 2020-09-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000110465920109133/0001104659-20-109133-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020005089/0001179110-20-005089-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006356/0001179110-20-006356-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006601/0001179110-20-006601-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006602/0001179110-20-006602-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006603/0001179110-20-006603-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006604/0001179110-20-006604-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006605/0001179110-20-006605-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006606/0001179110-20-006606-index.htm |
| 2020-05-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006611/0001179110-20-006611-index.htm |
| 2020-10-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1709401/000117911020010359/0001179110-20-010359-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000119312519036248/0001193125-19-036248-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1709401/000142284920000105/0001422849-20-000105-index.htm |
| 2019-03-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1709401/000155837019002516/0001558370-19-002516-index.htm |
| 2019-05-15 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1709401/000155837019005041/0001558370-19-005041-index.htm |
| 2019-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1709401/000155837019005043/0001558370-19-005043-index.htm |
| 2019-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000155837019005047/0001558370-19-005047-index.htm |
| 2019-05-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1709401/000155837019005049/0001558370-19-005049-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000155837019008018/0001558370-19-008018-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000155837019010992/0001558370-19-010992-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1709401/000155837020002475/0001558370-20-002475-index.htm |
| 2020-03-12 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1709401/000155837020002477/0001558370-20-002477-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000155837020006124/0001558370-20-006124-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1709401/000155837020010055/0001558370-20-010055-index.htm |
| 2018-07-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1709401/999999999518001813/9999999995-18-001813-index.htm |
| 2019-08-21 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1709401/999999999519001940/9999999995-19-001940-index.htm |
Rubius Therapeutics, Inc (RUBY) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rubius Therapeutics, Inc (RUBY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 799%Institutional Ownership: 9480%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-01-14 | ROBERT LANGER | Director | Sell | 7,500.00 | 14.59 | 109,443.75 | 0.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm |
| 2019-04-15 | ROBERT LANGER | Director | Sell | 7,500.00 | 17.57 | 131,799.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm |
| 2019-07-15 | ROBERT LANGER | Director | Sell | 7,500.00 | 14.94 | 112,048.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm |
| 2019-10-14 | ROBERT LANGER | Director | Sell | 7,500.00 | 8.52 | 63,874.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm |
| 2018-07-20 | Roger Pomerantz | Director | Buy | 100.00 | 23.00 | 2,300.00 | 100.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046530/0001104659-18-046530-index.htm |
| 2018-07-20 | Francis M Cuss | Director | Buy | 10,000.00 | 23.00 | 230,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046528/0001104659-18-046528-index.htm |
| 2019-04-08 | TORBEN STRAIGHT NISSEN | President | Sell | 2,100.00 | 20.00 | 42,000.00 | 1,845,304.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919020731/0001104659-19-020731-index.htm |
| 2019-04-05 | TORBEN STRAIGHT NISSEN | President | Sell | 12,096.00 | 20.00 | 241,920.00 | 1,847,404.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm |
| 2019-04-03 | TORBEN STRAIGHT NISSEN | President | Sell | 500.00 | 20.00 | 10,000.00 | 1,859,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919020219/0001104659-19-020219-index.htm |
| 2020-04-22 | Christina M. Coughlin | Chief Medical Officer | Buy | 19,000.00 | 5.52 | 104,813.50 | 19,000.00 | https://www.sec.gov/Archives/edgar/data/1709401/000117911020005089/0001179110-20-005089-index.htm |
| 2019-07-24 | TORBEN STRAIGHT NISSEN | President | Buy | 175,000.00 | 0.18 | 31,500.00 | 2,020,304.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm |
| 2019-07-24 | TORBEN STRAIGHT NISSEN | President | Buy | 32,146.00 | 0.19 | 6,107.74 | 2,052,450.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919042118/0001104659-19-042118-index.htm |
| 2020-04-14 | PABLO J CAGNONI | CEO and President | Buy | 21,000.00 | 4.70 | 98,693.70 | 21,000.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465920047001/0001104659-20-047001-index.htm |
| 2018-07-20 | Catherine A. Sohn | Director | Buy | 2,500.00 | 23.00 | 57,500.00 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046532/0001104659-18-046532-index.htm |
| 2018-07-20 | Jonathan Symonds | Director | Buy | 25,000.00 | 23.00 | 575,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465918046526/0001104659-18-046526-index.htm |
| 2019-01-22 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 34,843.00 | 2.87 | 99,999.41 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919003193/0001104659-19-003193-index.htm |
| 2019-03-15 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 48,000.00 | 15.84 | 760,113.60 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm |
| 2019-06-17 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 18,500.00 | 14.10 | 260,868.50 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-06-18 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 10,858.00 | 14.27 | 154,957.78 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-06-19 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 18,399.00 | 13.80 | 253,867.56 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-06-20 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 243.00 | 13.93 | 3,385.96 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm |
| 2019-09-16 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 36,123.00 | 10.13 | 365,897.09 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm |
| 2019-09-17 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 11,877.00 | 10.05 | 119,309.22 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm |
| 2019-12-16 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Sell | 48,000.00 | 13.48 | 646,900.80 | 34,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm |
| 2019-06-20 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 243.00 | 2.87 | 697.41 | 35,086.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919037241/0001104659-19-037241-index.htm |
| 2019-06-18 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 10,858.00 | 2.87 | 31,162.46 | 45,701.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-09-17 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 11,877.00 | 2.87 | 34,086.99 | 46,720.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm |
| 2020-03-13 | David R Epstein | Director | Buy | 5,000.00 | 3.82 | 19,100.00 | 4,805,453.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm |
| 2020-03-13 | David R Epstein | Director | Buy | 5,000.00 | 4.00 | 20,000.00 | 4,810,453.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465920034857/0001104659-20-034857-index.htm |
| 2020-03-17 | David R Epstein | Director | Buy | 5,000.00 | 3.76 | 18,800.00 | 4,815,453.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465920036113/0001104659-20-036113-index.htm |
| 2020-05-15 | ANDREW M. OH | Chief Financial Officer | Buy | 5,000.00 | 4.74 | 23,700.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1709401/000117911020006356/0001179110-20-006356-index.htm |
| 2019-06-19 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 18,399.00 | 2.87 | 52,805.13 | 53,242.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-06-17 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 18,500.00 | 2.87 | 53,095.00 | 53,343.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919036506/0001104659-19-036506-index.htm |
| 2019-09-16 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 36,123.00 | 2.87 | 103,673.01 | 70,966.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919050627/0001104659-19-050627-index.htm |
| 2019-01-14 | ROBERT LANGER | Director | Buy | 7,500.00 | 0.15 | 1,125.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919002512/0001104659-19-002512-index.htm |
| 2019-04-15 | ROBERT LANGER | Director | Buy | 7,500.00 | 0.15 | 1,125.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919022064/0001104659-19-022064-index.htm |
| 2019-07-15 | ROBERT LANGER | Director | Buy | 7,500.00 | 0.15 | 1,125.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919040757/0001104659-19-040757-index.htm |
| 2019-10-14 | ROBERT LANGER | Director | Buy | 7,500.00 | 0.15 | 1,125.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919054477/0001104659-19-054477-index.htm |
| 2019-03-15 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 48,000.00 | 2.87 | 137,760.00 | 82,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919016067/0001104659-19-016067-index.htm |
| 2019-12-16 | CHRISTOPHER L. CARPENTER | Chief Medical Officer | Buy | 48,000.00 | 2.87 | 137,760.00 | 82,843.00 | https://www.sec.gov/Archives/edgar/data/1709401/000110465919073955/0001104659-19-073955-index.htm |